River Exchange, a US Bitcoin financial services company, has sued an unnamed Canadian Bitcoin mining firm for about $6.7 million in unpaid refunds following the cancellation of their contract. The dispute highlights ongoing issues in the Bitcoin mining industry involving cross-border agreements and payment disputes. The Canadian miner's identity remains undisclosed, suggesting it may be a private company. This case adds to a pattern of legal conflicts between US financial firms and Canadian miners, often related to contract terminations or service disagreements.
The story about River Exchange suing a Canadian Bitcoin miner for $6.7 million provides context for cryptocurrency market activity. For readers following cryptocurrency, here is Pluang's market snapshot as of Sep 27, 2026 03:21 WIB: out of 50 major cryptocurrencies, 22 rose and 27 fell. XRP was priced at Rp27.226 with a 1-day change of -3.05%, while ATOM rose 2.60% to Rp32.746, and ALGO increased 2.33% to Rp2.111.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
